Acino International AG
https://acino.swiss.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Acino International AG
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Aspen Offloads Six In South Africa With Debt Still A Priority
South Africa’s Aspen Pharmacare is continuing along the path of offloading assets that no longer fit into its strategy, using the proceeds to pay off its substantial debt pile and reinvest in areas of greater strategic focus. Half-a-dozen products currently offered in its local market are now on their way to Switzerland’s Acino.
Celltrion Strikes $278m Deal With Takeda
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Acino Holding AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice